Last Updated on December 31, 2023 by The Health Master
Avenue Therapeutics, focused on the development of intravenous (IV) tramadol for the US market, announced that it has received a second Complete Response Letter (CRL) from the US Food and Drug Administration (USFDA) regarding its New Drug Application (NDA) seeking approval for IV tramadol.
The CRL stated that the delayed and unpredictable onset of analgesia with IV tramadol does not support its benefit as a monotherapy to treat patients in acute pain, and there is insufficient information to support that IV tramadol in combination with other analgesics is safe and effective for the intended patient population.
The USFDA did not identify any Chemistry, Manufacturing and Controls (CMC) issues in this CRL. A company statement said, “Avenue disagrees with the FDA’s interpretation of the data in the NDA and intends to continue to pursue regulatory approval for IV tramadol.”
Avenue Therapeutics is Cipla’s step-down associate company in the US.
Natco gets USFDA nod for Carfilzomib Injection
Lupin gets warning letter from USFDA for Somerset facility
Lupin gets USFDA nod for generic drug to treat HIV infection
Glenmark gets USFDA nod for Theophylline ER tablets
Zydus Cadila gets tentative USFDA nod for Osimertinib Tablets
Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets
Schedules: All types of Cosmetics
Self-use Rapid Antigen test kits: Coming soon at Pharmacies
Black fungus can be prevented with Ayush medicines: Experts
Zydus Cadila gets tentative USFDA nod for Epilepsy drug
Govt Job for Medical Officers (576 posts) under Public service Commission
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
